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Game, Set, Match for Factor VIII Mismatch?
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In this issue, Gunasekera et al1 provide evidence that the high rate of factor VIII (FVIII) 
inhibitors seen in Black hemophilia A (HA) patients is not due to a mismatch between the 
structure of treatment products and FVIII genotypes common in Blacks. Black HA patients 
have consistently been shown to have an almost two-fold higher frequency than White 
patients of inhibitors, the neutralizing antibodies that can develop against FVIII treatment 
products and limit their usefulness in stopping or preventing bleeding.2, 3 The mismatch 
hypothesis to explain this disparity was an innovative concept proposed by Viel et al4 based 
on their observation that the pattern of four non-synonymous single nucleotide 
polymorphisms (ns-SNPs) coding for amino acid changes in normal FVIII structure could be 
used to define 6 F8 haplotypes, the frequencies of which vary by race. The two most 
common haplotypes, H1 and H2, are represented in different full-length recombinant FVIII 
products used for HA treatment. Among 76 African Americans, 25% had haplotypes other 
than H1 and H2, and this group had increased odds of having an inhibitor (odds ratio, 3.6; 
95% confidence interval, 1.1–12.3; P=0.04).4 Subsequent studies of small populations of 
patients of African ancestry have failed to confirm this finding.5–7 The haplotypes 
investigated are rare in White populations, and no correlation with inhibitors was found in 
substantially sized groups of White patients.5, 8
Gunasekera et al1 present the most comprehensive study to date to address this question, 
using three different approaches. First, statistical analysis using 174 African-American 
patients and 198 Caucasian HA subjects confirmed the increased inhibitor frequency in 
African Americans but showed no correlation of inhibitor status with ns-SNPs or 
haplotypes. The only statistically significant finding was a higher inhibitor frequency in 
patients “potentially exposed to sequence-mismatched FVIII” than in those not exposed. As 
the authors note, this should be interpreted with caution. The exposed group included any 
patient who had ever received a blood product or plasma-derived factor, including FEIBA. 
Since FEIBA is used primarily to treat inhibitor patients, its inclusion may bias the results. 
Second, binding affinities of peptides containing the relevant ns-SNPs to HLA-DRB1 alleles 
were measured to identify SNP/allele combinations that might increase inhibitor risk. Weak 
or no binding was observed in 85% of these assays. Among subjects with combinations that 
did bind, more than 50% had not developed inhibitors. Binding was far less frequent than 
predicted by computer algorithms. Third, cultured CD4 T cells from a small number of 
patients infused with mismatched products were examined by tetramer-guided epitope 
mapping to determine reactivity with FVIII peptides containing the ns-SNP sequences. 
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Using methods that have successfully demonstrated T-cell epitopes in mild hemophilia 
patients with high-risk mutations resulting in single-amino-acid changes, they found no high 
avidity binding. The authors conclude that the small number of patients potentially reactive 
to the neo-epitopes presented by mismatched products could not account for the high 
inhibitor rate seen in African Americans.
If FVIII mismatch is not the answer, where do we go from here? Risk factors for 
development of inhibitors are complex and interrelated (Figure). The causative gene 
mutation is the primary determinant of inhibitor risk, controlling whether the gene produces 
a product, and, if so, how different that product is from the normal protein. More than 2500 
unique mutations causing HA have been reported (http://www.cdc.gov/
hemophiliamutations). This heterogeneity makes inclusion of mutation in risk factor analysis 
problematic. African-American HA patients have not been found to have differences from 
White Americans in the type and frequency of mutations, 4, 5 but mutation type has not been 
included in all analyses. The use of patient groups with the common intron-22 inversion to 
control for mutation presents an interesting conundrum. Studies have now shown that the 
inverted gene does produce two products, which include ns-SNPs and remain intracellular; 
they may result in immune tolerance.9 The uniformity of these products across all intron-22 
inversion patients has yet to be demonstrated.
Study of immune response genes is similarly daunting, although it presents perhaps the most 
likely area for identification of racial differences. Study of 13,331 SNPs in 833 subjects 
yielded 13 candidate genes for further investigation.10 This large population, however, 
included only 48 Black subjects. Larger numbers of Black patients and Hispanics, who also 
have increased inhibitor risk,2, 3 will be required to assess whether their immune risk factors 
differ from those in Whites. Functional studies of the type conducted by Gunasekera et al1 
will be necessary to evaluate the validity of any genetic risk factors identified.
Product exposure as a risk factor is an area of intense interest. Inhibitor risk is increased 
during the first few exposures in severe patients, although mild and moderate patients may 
have a lifelong risk. Inhibitors may be triggered by intense treatment episodes, 
inflammation, or other challenges to the immune system during therapy. Product structure 
differences and product switching remain areas of concern. The problem in risk factor 
analysis is documenting and quantifying exposure. With US reliance on multiple treatment 
products, it is difficult to identify patients who have received only a single factor product, 
other than previously untreated patients, who number fewer than 400 affected neonates per 
year. Assessment of the immunogenicity of individual products or treatment methods 
requires large numbers. Fewer than 1500 Black and 1500 Hispanic patients have been 
enrolled in surveillance programs in the US, and recruitment of sufficient numbers for 
studies has been difficult. Indeed, we have hypothesized that the increased numbers of 
inhibitors seen may result from attendance at hemophilia treatment centers and study 
enrollment by only the more severely affected inhibitor patients in these population groups.5
An assessment of all three components of risk is required to provide an individual patient 
with treatment designed to minimize the chance of an inhibitor occurring. Very large 
studies, perhaps conducted internationally, will be required to quantify these risks and to 
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assess the unique characteristics of population subgroups such as Blacks and Hispanics that 
result in their disproportionate risk.
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Risk factors for development of inhibitors (neutralizing antibodies) against treatment 
products used to stop or prevent bleeding in hemophilia patients include three major 
categories. The causative mutation in the gene for factor VIII or factor IX has been shown to 
be the most significant risk factor, as whether a gene product is produced or its structure 
determines how the immune system recognizes the infused protein. The treatment product 
itself, how much exposure has occurred, and conditions of that exposure provide the trigger 
for the immune response. Determinants within the immune system control the response 
through a multiplicity of genes producing a wide phenotypic variability. Interaction of these 
three components, illustrated by the overlapping circles of the Venn diagram, provides each 
person with hemophilia with a highly individualized risk of developing this complication of 
treatment at some point during his lifetime. Professional illustration by Ken Probst, 
XavierStudio.
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